Pharsight

Kybella patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8242294 ABBVIE Synthetic bile acid compositions and methods
May, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846066 ABBVIE Methods and related compositions for reduction of fat and skin tightening
Feb, 2025

(7 months from now)

US8298556 ABBVIE Methods and related compositions for the non-surgical removal of fat
Aug, 2025

(1 year, 1 month from now)

US7622130 ABBVIE Methods and compositions for the non-surgical removal of fat
Dec, 2027

(3 years from now)

US7754230 ABBVIE Methods and related compositions for reduction of fat
Dec, 2027

(3 years from now)

US8461140 ABBVIE Synthetic bile acid compositions and methods
Feb, 2028

(3 years from now)

US8546367 ABBVIE Synthetic bile acid compositions and methods
Feb, 2028

(3 years from now)

US9949986 ABBVIE Synthetic bile acid compositions and methods
Feb, 2028

(3 years from now)

US9636349 ABBVIE Synthetic bile acid compositions and methods
Feb, 2028

(3 years from now)

US9522155 ABBVIE Synthetic bile acid compositions and methods
Feb, 2028

(3 years from now)

US8883770 ABBVIE Synthetic bile acid compositions and methods
Feb, 2028

(3 years from now)

US8367649 ABBVIE Formulations of deoxycholic acid and salts thereof
Mar, 2030

(5 years from now)

US8101593 ABBVIE Formulations of deoxycholic acid and salts thereof
Mar, 2030

(5 years from now)

US10500214 ABBVIE Formulations of deoxycholic acid and salts thereof
Mar, 2030

(5 years from now)

US8653058 ABBVIE Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
Mar, 2030

(5 years from now)

Kybella is owned by Abbvie.

Kybella contains Deoxycholic Acid.

Kybella has a total of 15 drug patents out of which 0 drug patents have expired.

Kybella was authorised for market use on 29 April, 2015.

Kybella is available in solution;subcutaneous dosage forms.

Kybella can be used as improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as described in the approved labeling, method for reduction of submental fat.

The generics of Kybella are possible to be released after 02 March, 2030.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Market Authorisation Date: 29 April, 2015

Treatment: Method for reduction of submental fat; Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults by means of reducing submental fat volume as de...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of KYBELLA before it's drug patent expiration?
More Information on Dosage

KYBELLA family patents

Family Patents